GCF and Saliva Levels of IL-36α in Periodontal Disease
IL-36α Levels in Saliva and Gingival Crevicular Fluid of the Patients With Periodontal Disease
1 other identifier
interventional
80
1 country
1
Brief Summary
Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 10, 2025
CompletedFirst Submitted
Initial submission to the registry
March 17, 2026
CompletedFirst Posted
Study publicly available on registry
March 27, 2026
CompletedMarch 27, 2026
March 1, 2026
1.1 years
March 17, 2026
March 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
IL-36α levels
IL-36α levels in the gingival crevicular fluid (GCF) and saliva of the all groups
Baseline
Secondary Outcomes (5)
Plaque index (PI)
Baseline
Gingival index (GI)
Baseline
Probing pocket depth (PPD)
Baseline
Clinical attachment level (CAL)
Baseline
Bleeding on probing (BOP)
Baseline
Study Arms (4)
Control group
OTHERPeriodontally and systemically healthy individuals
Gingivitis
OTHERSystemically healthy and patients with Gingivitis
Stage III Grade B Periodontitis
OTHERsystemically healthy and patients with Stage III Grade B periodontitis
Stage III Grade C Periodontitis
OTHERsystemically healthy and patients with Stage III Grade C periodontitis
Interventions
Collection of Gingival crevicular fluid and saliva from all patients at baseline.
Eligibility Criteria
You may qualify if:
- at least 20 teeth
- older than 18 years
You may not qualify if:
- any systemic disease
- pregnant or lactating
- history of radiotherapy or chemotherapy
- used antibiotics or any anti-inflammatory medication
- smokers
- had undergone periodontal treatment within the previous 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ordu Universitylead
Study Sites (1)
Ordu University
Ordu, 52100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
March 17, 2026
First Posted
March 27, 2026
Study Start
December 10, 2023
Primary Completion
January 10, 2025
Study Completion
January 10, 2025
Last Updated
March 27, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
No, sharing the IPD data is currently being considered.